Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis

Area of Science:

• Virology
• Dermatology
• Pharmacology

Background:

• Recurrent herpes simplex labialis (cold sores) significantly impacts quality of life.
• Prophylactic antiviral therapy is explored to manage frequent outbreaks.
• Topical and oral acyclovir are common treatment options.

Purpose of the Study:

• To evaluate the efficacy of prophylactic topical and peroral acyclovir for herpes simplex labialis suppression.
• To compare the effectiveness of acyclovir prophylaxis between herpes labialis and herpes genitalis.
• To investigate the response of different herpes labialis lesion types to acyclovir.

Main Methods:

• Systematic review of 11 clinical trials on prophylactic acyclovir for herpes simplex labialis.
• Analysis of acyclovir dosage and efficacy in reducing lesion frequency.
• Examination of acyclovir's effect on herpes labialis induced by ultraviolet radiation.

Main Results:

• Prophylactic topical acyclovir demonstrated minimal effectiveness.
• Prophylactic oral acyclovir (400-1,000 mg/day) reduced herpes labialis frequency by 50-78%.
• Acyclovir prophylaxis showed a lower suppression rate for herpes labialis (50-78%) compared to herpes genitalis (80-90%).
• Immediate lesions post-UV radiation (within 48 hours) were not suppressed by acyclovir.

Conclusions:

• Oral acyclovir is an effective prophylactic treatment for recurrent herpes simplex labialis.
• Topical acyclovir is largely ineffective for herpes labialis suppression.
• Atypical pathogenesis of immediate lesions may explain lower efficacy compared to genital herpes.